

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Nanjing Leads Biolabs Co., Ltd.
南京维立志博生物科技股份有限公司

(A joint stock company established in the People's Republic of China with limited liability)

(Stock Code: 9887)

VOLUNTARY ANNOUNCEMENT
VOLUNTARY EXTENSION OF LOCK-UP
PERIOD GIVEN BY THE CHIEF EXECUTIVE OFFICER

This announcement is made by Nanjing Leads Biolabs Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis.

Reference is made to the prospectus of the Company dated July 17, 2025 (the “**Prospectus**”). Unless otherwise defined, terms used herein shall have the same meaning as defined in the Prospectus.

The Company has recently received a notice of undertaking (the “**Extension Undertaking**”) from Dr. Kang Xiaoqiang (“**Dr. Kang**”), the co-founder of the Group, the chairman of our Board, an executive Director, the chief executive officer and the general manager of the Company, regarding the voluntary extension of the lock-up period of all 7,874,617 H Shares directly held by him (the “**Shares**”).

Pursuant to the PRC Company Law, at any time during the period commencing on the Listing Date and ending on a date which is 12 months from the Listing Date, Dr. Kang will not offer, pledge, sell, transfer or otherwise dispose of his Shares (the “**Original Lock-up Period**”). The Original Lock-up Period ends on July 24, 2026.

Pursuant to the Extension Undertaking, as Dr. Kang remains positive of the growth potential, core competitiveness and industry prospects of the Company from a long-term perspective, and to safeguard the stability of the share price of the Company and capital market confidence, as well as the legitimate rights and interests of the shareholders of the Company, particularly the minority shareholders, Dr. Kang has undertaken to extend the Original Lock-up Period in respect of the Shares for an additional six (6) months, up to and including January 24, 2027. During such extended lock-up period, Dr. Kang will not, in any manner, directly or indirectly, dispose of or otherwise reduce the Shares directly held by him.

The Company believes that the Extension Undertaking demonstrates the confidence of Dr. Kang in the future prospects and long term value of the Company.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the Company's shares.

By order of the Board
Nanjing Leads Biolabs Co., Ltd.
南京维立志博生物科技股份有限公司
Dr. KANG XIAOQIANG
*Chairman, Executive Director and
Chief Executive Officer*

Nanjing, PRC, July 24, 2026

As at the date of this announcement, the board of directors of the Company comprises: (i) Dr. Kang Xiaoqiang (Chairman of the Board), Dr. Lai Shoupeng and Mr. Zuo Honggang as executive Directors; (ii) Mr. Zhang Yincheng, Dr. Chen Renhai and Dr. Wu Fenglan as non-executive Directors; and (iii) Dr. Zhang Hongbing, Mr. Du Yilong and Ms. Du Jiliu as independent non-executive Directors.